Commerce Bank Takes Position in Elanco Animal Health Incorporated $ELAN

Commerce Bank bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 37,614 shares of the company’s stock, valued at approximately $926,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. NewEdge Advisors LLC grew its holdings in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Elanco Animal Health during the second quarter valued at about $38,000. Root Financial Partners LLC raised its holdings in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health during the 4th quarter worth about $41,000. Finally, Torren Management LLC bought a new position in shares of Elanco Animal Health during the 4th quarter worth about $46,000. 97.48% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on ELAN shares. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 20th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. KeyCorp increased their price target on Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Finally, JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and an average price target of $29.09.

Insider Buying and Selling at Elanco Animal Health

In related news, CFO Robert M. Vanhimbergen acquired 4,200 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $23.08 per share, with a total value of $96,936.00. Following the acquisition, the chief financial officer owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul Herendeen acquired 10,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $23.68 per share, with a total value of $236,800.00. Following the completion of the acquisition, the director directly owned 111,687 shares in the company, valued at approximately $2,644,748.16. This represents a 9.83% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is currently owned by corporate insiders.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $25.09 on Thursday. The firm has a market capitalization of $12.54 billion, a price-to-earnings ratio of -61.20, a price-to-earnings-growth ratio of 1.50 and a beta of 1.67. The firm’s fifty day moving average price is $24.61 and its two-hundred day moving average price is $24.01. Elanco Animal Health Incorporated has a 1-year low of $17.11 and a 1-year high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the previous year, the firm posted $0.26 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.